SELLAS Life Sciences Group (SLS) Price & Analysis

Compare

1,050 Followers

SLS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.77 - $2.27

Previous CloseN/A

Volume1.43M

Average Volume (3M)3.15M

Market Cap

$161.64M

Enterprise Value$67.15M

Total Cash (Recent Filing)$28.40M

Total Debt (Recent Filing)$870.00K

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Nov 12, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding99,777,490

10 Day Avg. Volume1,701,386

30 Day Avg. Volume3,149,788

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.42

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-2.40

Forecast

1Y Price Target

$7.25

Price Target Upside347.53% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Efficacy DataPositive SLS009 data hitting all its endpoints in relapsed/refractory AML P2a with plans to move to front-line AML.

Regulatory ProgressSellas has FDA guidance to move the triplet now to 1L AML, which represents a significant positive for Sellas as it progresses this program.

Bears Say

Stock PerformanceSLS shares are down as much as 26%, possibly due to a slight run-up ahead of the data and some profit taking, as well as continued pressure in the biotech sector.

SELLAS Life Sciences Group News

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sequans (SQNS) 85.88% +1.67,...

21h ago

FAZ

Sellas Life announces IDMC completed pre-specified analysis of Phase 3 REGAL

SELLAS Life Sciences (SLS) announced that the Independent Data Monitoring Committee, IDMC, has completed a pre-specified analysis of...

21h ago

SLS

Sellas Life Sciences price target raised to $7 from $4 at Maxim

Maxim raised the firm’s price target on Sellas Life Sciences (SLS) to $7 from $4 and keeps a...

23d ago

SLS

Sellas Life Sciences meets all primary endpoints in Phase 2 trial of SLS009

SELLAS Life Sciences (SLS) Group announced that is has met all primary endpoints in its Phase 2 trial...

24d ago

SLS

SLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Sellas Life Sciences Group (SLS) is scheduled to report 2nd quarter earnings on 08/07/2025. Regarding Q2 estimates, Wall...

3d ago

SLS

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

SELLAS Life Sciences (SLS) announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board. Dr....

1M ago

SLS

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Ocugen (OCGN) 233.66% +35.18,...

1M ago

JBS

RKT

Sellas Life Sciences to be added to Russell 3000, Russell 2000 indexes

SELLAS Life Sciences (SLS) announced that the Company will be added to the Russell 3000 and Russell 2000...

1M ago

SLS

SELLAS Life Sciences Holds Annual Stockholders Meeting

SELLAS Life Sciences Group ( ($SLS) ) has issued an announcement. On June 17, 2025, SELLAS Life Sciences...

2M ago

SLS

Sellas Life Sciences expands SAB with Philip Amrein, Alex Kentsis

SELLAS Life Sciences (SLS) Group announced the appointment of two oncology leaders to its Scientific Advisory Board. The...

2M ago

SLS

Promising Developments and Upcoming Catalysts Drive Buy Rating for SELLAS Life Sciences Group

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on SELLAS Life Sciences Group (SLS –...

2M ago

SLS

Sellas Life Sciences presents preclinical efficacy data on SLS009

SELLAS Life Sciences (SLS) announced preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer lines. The data are...

2M ago

SLS

Sellas Life Sciences Reports Improved Financial Position

Sellas Life Sciences Group ( ($SLS) ) has released its Q1 earnings. Here is a breakdown of the...

3M ago

SLS

Promising Catalysts and Strong Financial Position Drive Buy Rating for SELLAS Life Sciences Group

SELLAS Life Sciences Group (SLS – Research Report), the Healthcare sector company, was revisited by a Wall Street...

3M ago

SLS

SLS FAQ

What was Sellas Life Sciences Group’s price range in the past 12 months?

Sellas Life Sciences Group lowest stock price was $0.77 and its highest was $2.27 in the past 12 months.

What is Sellas Life Sciences Group’s market cap?

Sellas Life Sciences Group’s market cap is $161.64M.

When is Sellas Life Sciences Group’s upcoming earnings report date?

Sellas Life Sciences Group’s upcoming earnings report date is Nov 12, 2025 which is in 96 days.

How were Sellas Life Sciences Group’s earnings last quarter?

Currently, no data Available

Is Sellas Life Sciences Group overvalued?

According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sellas Life Sciences Group pay dividends?

Sellas Life Sciences Group does not currently pay dividends.

What is Sellas Life Sciences Group’s EPS estimate?

Sellas Life Sciences Group’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sellas Life Sciences Group have?

Sellas Life Sciences Group has 99,777,490 shares outstanding.

What happened to Sellas Life Sciences Group’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Sellas Life Sciences Group?

Among the largest hedge funds holding Sellas Life Sciences Group’s share is Highbridge Capital Management LLC. It holds Sellas Life Sciences Group’s shares valued at 0.

SELLAS Life Sciences Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

-144.90%

Trailing 12-Months

Asset Growth

43.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sellas Life Sciences Group

SELLAS Life Sciences Group (SLS) is a biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. The company's core product is galinpepimut-S (GPS), which is designed to stimulate an immune response against specific cancer cells. SELLAS is involved in clinical trials and research collaborations to advance its pipeline and bring innovative cancer treatments to market.

SELLAS Life Sciences Group (SLS) Earnings & Revenues

Historic Earnings Reports

SLS Stock 12 Month Forecast

Average Price Target

$7.25

▲(347.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.496923076923077,2.913846153846154,3.3307692307692305,3.747692307692308,4.164615384615384,4.581538461538461,4.998461538461538,5.415384615384616,5.832307692307692,6.249230769230769,6.666153846153846,7.083076923076923,{"y":7.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.477692307692308,2.8753846153846156,3.273076923076923,3.670769230769231,4.068461538461539,4.466153846153846,4.863846153846154,5.2615384615384615,5.659230769230769,6.056923076923077,6.454615384615384,6.852307692307692,{"y":7.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,2.4584615384615387,2.836923076923077,3.2153846153846155,3.5938461538461537,3.9723076923076923,4.350769230769231,4.729230769230769,5.107692307692307,5.486153846153846,5.864615384615385,6.243076923076923,6.621538461538462,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.07,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >